Market Place
Sourcing Support
Editas Medicine to Participate in Upcoming Investor Conferences
06 Nov 2024 //
GLOBENEWSWIRE
Editas Medicine Announces Q3 2024 Results and Business Updates
04 Nov 2024 //
GLOBENEWSWIRE
Editas Medicine Announces Progress Towards 2024 Goals
22 Oct 2024 //
GLOBENEWSWIRE
Editas prioritizes in vivo therapies, seeks reni-cel partner
22 Oct 2024 //
FIERCE BIOTECH
Editas Medicine And Genevant Collaborate On mRNA-LNP Therapeutics
21 Oct 2024 //
GLOBENEWSWIRE
Editas Medicine Hosts Strategic Update Webinar On 2024 Goals
18 Oct 2024 //
GLOBENEWSWIRE
Editas sells future CRISPR license fees; Plus, news about Oncolytics Biotech
05 Oct 2024 //
ENDPTS
Editas cashes in on Vertex Cas9 licensing agreement for $57M
04 Oct 2024 //
FIERCE BIOTECH
Editas Medicine Announces $50M+ Monetization Deal With DRI Healthcare
03 Oct 2024 //
GLOBENEWSWIRE
Editas Medicine to Participate in Upcoming Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
07 Aug 2024 //
GLOBENEWSWIRE
Editas Medicine To Report Q2 2024 Results
31 Jul 2024 //
GLOBENEWSWIRE
Editas Reports New Reni-Cel Data In Beta Thalassemia At EHA
14 Jun 2024 //
GLOBENEWSWIRE
Editas Reports New Reni-Cel Data In Sickle Cell At EHA 2024
14 Jun 2024 //
GLOBENEWSWIRE
Editas To Present RUBY, EdiTHAL Reni-cel Data At EHA 2024
14 May 2024 //
GLOBENEWSWIRE
Editas In Vivo Gene Editing Data At ASGCT 2024
10 May 2024 //
GLOBENEWSWIRE
How Editas `dragged` new CSO over after 37 years at Biogen
10 May 2024 //
FIERCE BIOTECH
Editas Medicine Announces First Quarter 2024 Results and Business Updates
08 May 2024 //
GLOBENEWSWIRE
Editas Q1 2024 Results Call, Investor Events
02 May 2024 //
GLOBENEWSWIRE
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
01 May 2024 //
GLOBENEWSWIRE
Editas Preclinical In Vivo Pipeline Data At ASGCT Meeting
22 Apr 2024 //
GLOBENEWSWIRE
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results
28 Feb 2024 //
GLOBENEWSWIRE
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results
21 Feb 2024 //
GLOBENEWSWIRE
Editas Medicine to Participate in Upcoming Investor Conferences
31 Jan 2024 //
GLOBENEWSWIRE
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities
08 Jan 2024 //
GLOBENEWSWIRE
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Vertex pays Editas $100M to use gene-editing tech
13 Dec 2023 //
FIERCE BIOTECH
Editas Announces New EDIT-301 Safety and Efficacy Data in 17 Patients Presented
11 Dec 2023 //
GLOBENEWSWIRE
ASH: Editas shares data for mid-stage sickle cell disease asset
11 Dec 2023 //
FIERCE BIOTECH
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
03 Nov 2023 //
GLOBENEWSWIRE
Editas Medicine to Present Data from the RUBY and EdiTHAL Trials of EDIT-301
02 Nov 2023 //
GLOBENEWSWIRE
Editas Medicine Announces Third Quarter 2023 Results Conference Call
27 Oct 2023 //
GLOBENEWSWIRE
Editas Medicine Granted FDA RMAT Designation for EDIT-301
16 Oct 2023 //
GLOBENEWSWIRE
Editas Medicine Appointed Caren Deardorf as Chief Commercial Officer
25 Sep 2023 //
GLOBENEWSWIRE
Editas Medicine Reports Inducement Grants to New Chief Commercial Officer
25 Sep 2023 //
GLOBENEWSWIRE
Editas Medicine Announces Upcoming Investor Events
30 Aug 2023 //
GLOBENEWSWIRE
Editas & Azzur Expand Partnership to Accelerate Editas Manufacturing Capabilities
27 Jul 2023 //
GLOBENEWSWIRE
Editas Medicine Announces Second Quarter 2023 Results Conference Call
26 Jul 2023 //
GLOBENEWSWIRE
Editas Medicine Reports Inducement Grant to New Chief Scientific Officer
25 Jul 2023 //
GLOBENEWSWIRE
Editas Medicine Appoints Linda C. Burkly, Ph.D., as Chief Scientific Officer
24 Jul 2023 //
GLOBENEWSWIRE
After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock?
20 Jun 2023 //
FOOL
Editas Medicine Announces Offering of Common Stock
14 Jun 2023 //
GLOBENEWSWIRE
Editas Medicine Announces Pricing of Offering of Common Stock
14 Jun 2023 //
GLOBENEWSWIRE
Editas gives first look at CRISPR data in sickle cell after layoffs
09 Jun 2023 //
ENDPTS
Editas Medicine Announces Positive EDIT-301 Safety Data from RUBY Trial
09 Jun 2023 //
GLOBENEWSWIRE
Editas to Host Event to Discuss EDIT-301 Clinical Data from the RUBY Trial
06 Jun 2023 //
GLOBENEWSWIRE
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
18 May 2023 //
GLOBENEWSWIRE
Editas Medicine Announces Appointment of Erick J. Lucera as CFO
16 May 2023 //
GLOBENEWSWIRE
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301
11 May 2023 //
GLOBENEWSWIRE
Editas Medicine Announces First Quarter 2023 Results and Business Updates
05 May 2023 //
GLOBENEWSWIRE
Editas Medicine Announces Publication in Nature Biotechnology
01 May 2023 //
GLOBENEWSWIRE
Editas Medicine Announces First Quarter 2023 Results Conference Call
01 May 2023 //
GLOBENEWSWIRE
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301
27 Apr 2023 //
GLOBENEWSWIRE
Editas Strengthens Board Of Directors With Appointment Of Chair & Director
13 Apr 2023 //
PRESS RELEASE
Editas Medicine Strengthens Board of Directors with Appointment of New Chair
13 Apr 2023 //
GLOBENEWSWIRE
Editas Announces Fourth Quarter and Full Year 2022 Results and Business Updates
22 Feb 2023 //
GLOBENEWSWIRE
Editas to Host Conference Discussing Fourth Quarter and Full Year 2022 Results
15 Feb 2023 //
GLOBENEWSWIRE
Editas, in next restructuring step, to sell cell therapy work to Shoreline
20 Jan 2023 //
BIOPHARMADIVE
Editas touts skinnier pipeline after major shake-up
11 Jan 2023 //
FIERCE BIOTECH
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
09 Jan 2023 //
GLOBENEWSWIRE
